Therefore, clinical targeting of ribosomal proteins either through newer generation of EP300/CREBBP inhibitors or directly targeting ribosomes may be a promising strategy to treat advanced PCa in the future. The gene discussed is EP300; the disease is posterior cortical atrophy.